Neurotech International Ltd has released a press release.
NTI Receives Ethics Approval to Commence Human PK Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurotech International Ltd. on 6ix
Earlier from Neurotech International
- Positive Genomic Effects of NTI164 in PANDAS/PANS Patients
- Neurotech Appoints Dr Anthony Filippis as MD/CEO
- US FDA Response to Orphan Drug Request in PANDAS/PANS
- NTI164 Reverses Immune Dysregulation in PANDAS/PANS Children
- Neurotech Global Partnering and Registration Strategy
Later from Neurotech International
- Neurotech Receives US ODD in Rett Syndrome
- Neurotech Receives $2.44 Million R&D Tax Incentive Refund
- NTI Signs Development Agreement for Cannabinoid Therapies
- Positive Opinion on OMPD for NTI164 in Europe
- Appendix 4D and Half Year Accounts
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International